Short Interest in Genmab A/S (OTCMKTS:GNMSF) Increases By 9.4%

Genmab A/S (OTCMKTS:GNMSF) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 119,300 shares, an increase of 9.4% from the November 30th total of 109,000 shares. Based on an average daily volume of 4,500 shares, the short-interest ratio is presently 26.5 days.

Genmab A/S Trading Down 0.8 %

OTCMKTS GNMSF opened at $207.38 on Thursday. The company has a fifty day simple moving average of $214.23 and a 200 day simple moving average of $241.92. Genmab A/S has a 12-month low of $192.20 and a 12-month high of $334.33. The company has a market cap of $13.56 billion, a P/E ratio of 19.94 and a beta of 1.03.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.